Publications by authors named "S Rangaraj"

Background: Awareness of paediatric-specific predictors of damage in Childhood-lupus is needed to inform mitigation measures.

Objectives: To ascertain how clinical and demographic variables correlate with damage accrual and identify predictors of damage.

Methods: Analysis included UK JSLE Cohort Study participants.

View Article and Find Full Text PDF

Reactivation of fetal hemoglobin (HbF) is a commonly adapted strategy to ameliorate β-hemoglobinopathies. However, the continued production of defective adult hemoglobin (HbA) limits HbF tetramer production affecting the therapeutic benefits. Here, we evaluated deletional hereditary persistence of fetal hemoglobin (HPFH) mutations and identified an 11-kb sequence, encompassing putative repressor region (PRR) to β-globin exon-1 (βE1), as the core deletion that ablates HbA and exhibits superior HbF production compared with HPFH or other well-established targets.

View Article and Find Full Text PDF
Article Synopsis
  • A solvent casting technique was employed to create biomimetic nanocomposite scaffolds using varying concentrations of Curcumin-loaded gold nanoparticles (Cur-AuNPs) combined with chitosan-sodium alginate.
  • The physicochemical properties of the Cur-AuNPs and the resulting nanocomposites were analyzed through various characterization methods, focusing on their biocompatibility and antibacterial activity.
  • These studies indicate that Cur-AuNPs integrated with biomimetic nanocomposites have potential applications for nanotheranostics in targeted therapies.
View Article and Find Full Text PDF

Objectives: Juvenile-onset systemic lupus erythematosus (jSLE) affects 15-20% of lupus patients. Clinical heterogeneity between racial groups, age groups and individual patients suggests variable pathophysiology. This study aimed to identify highly penetrant damaging mutations in genes associated with SLE/SLE-like disease in a large national cohort (UK JSLE Cohort Study) and compare demographic, clinical and laboratory features in patient sub-cohorts with 'genetic' SLE vs remaining SLE patients.

View Article and Find Full Text PDF
Article Synopsis
  • - The study explores treatment plans for Juvenile-onset Systemic Lupus Erythematosus (JSLE) using data from a UK cohort collected over a span of 11 years, due to limited clinical trial evidence.
  • - Mycophenolate mofetil (MMF) was identified as the most frequently used immunomodulating drug, particularly for patients with renal involvement, with many requiring multiple medications.
  • - Of the 197 patients analyzed, a majority were treated with two or more immunomodulators, with MMF being the first and second line choice, and Rituximab often used as the third line option.
View Article and Find Full Text PDF